Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 10/20 | 0.42 |
| ▸ | ACVR1B | P36896 | 9/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656254 | 0.89 | BUB1 (0.43) | TGFBR1ACVRL1ACVR1BPRKD3PRKD1 | |
| SCHEMBL14223509 | 0.88 | TGFBR1 (0.47) | TGFBR1ACVRL1ACVR1BPRKD3PRKD1 | |
| SCHEMBL13649284 | 0.83 | TGFBR1 (0.58) | TGFBR1ACVRL1ACVR1BACVR1BUB1 | |
| SCHEMBL2128393 | 0.76 | TGFBR1 (0.66) | TGFBR1ACVRL1ACVR1BPRKD3PRKD1 | |
| SCHEMBL8348218 | 0.75 | TGFBR1 (0.42) | TGFBR1ACVRL1ACVR1BPRKD3PRKD1 | |
| SCHEMBL8346587 | 0.74 | TGFBR1 (0.47) | TGFBR1ACVRL1ACVR1BPRKD3PRKD1 | |
| SCHEMBL8347168 | 0.73 | TGFBR1 (0.47) | TGFBR1ACVRL1ACVR1BPRKD3PRKD1 | |
| SCHEMBL8347025 | 0.72 | TGFBR1 (0.43) | TGFBR1ACVRL1ACVR1BPRKD3PRKD1 | |
| SCHEMBL8348254 | 0.72 | TGFBR1 (0.43) | TGFBR1ACVRL1ACVR1BPRKD3PRKD1 | |
| SCHEMBL8345885 | 0.72 | TGFBR1 (0.45) | TGFBR1ACVRL1ACVR1BPRKD3PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | HAVCR2, EIF2AK2, MAVS | TGFBR1 3765/4885ACVRL1 4277/4885ACVR1B 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.